Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arz...
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.